AriBio Co., Ltd. is set to become the first South Korean pharma firm to begin a global Phase III clinical development program for a novel drug for Alzheimer’s disease (AD), following an IND approval from the domestic Ministry of Food and Drug Safety for the Polaris-AD study.
The multinational Phase III trial with the small molecule PDE5 inhibitor AR1001 is set to progress in the US, Europe and China, as well as South Korea, with a goal...